Hutchmed (China) Limited - American Depositary Shares (HCM) closed at $13.80 on October 27, 2026, down 3.3% from the previous close, on volume of 32,997 shares (30-day average 50,610).
Data as of October 27, 2026.
CICC Remains a Buy on HUTCHMED (China) (HCM)
TipRanks (Wed, 28-Oct 1:25 AM ET)
HUTCHMED Sets November 5 Webcast to Spotlight Phase III Savolitinib Data in MET-Driven NSCLC
Market Chameleon (Tue, 27-Oct 3:15 AM ET)
Globe Newswire (Mon, 26-Oct 8:00 PM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Mon, 26-Oct 6:55 AM ET)
Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)
TipRanks (Mon, 26-Oct 6:38 AM ET)
Globe Newswire (Mon, 26-Oct 4:30 AM ET)
Globe Newswire (Sun, 25-Oct 8:00 PM ET)
AstraZeneca stomach cancer drug doubles survival in late-stage trial
Seeking Alpha News (Sun, 25-Oct 12:17 PM ET)
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Globe Newswire (Tue, 20-Oct 8:00 PM ET)
Globe Newswire (Mon, 28-Sep 8:00 PM ET)
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Hutchmed (China) Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol HCM.
As of October 28, 2026, HCM stock price declined to $13.36 with 10,867 million shares trading.
HCM has a beta of 1.07, meaning it tends to be more sensitive to market movements. HCM has a correlation of 0.12 to the broad based SPY ETF.
HCM has a market cap of $2.32 billion. This is considered a Mid Cap stock.
In the last 3 years, HCM traded as high as $21.92 and as low as $9.77.
The top ETF exchange traded funds that HCM belongs to (by Net Assets): SPDW, DFEM, DFAX, DFSE.
HCM has underperformed the market in the last year with a price return of -10.1% while the SPY ETF gained +13.6%. However, in the short term, HCM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.1% vs +4.6% return in SPY. But in the last 2 weeks, HCM shares have been beat by the market, returning -1.0% compared to an SPY return of -0.9%.
HCM support price is $13.42 and resistance is $14.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCM shares will trade within this expected range on the day.